Kaplan Johanne 4

What Happened
Johanne Kaplan, Chief Development Officer of ProMIS Neurosciences (PMN), acquired 2,060 common shares and received Common Share purchase warrants to buy 2,060 additional common shares through a Securities Purchase Agreement on February 3, 2026. The reported per-share purchase price was $12.13; the filing shows $24,988 for the common shares and the footnote indicates the same $12.13 price applied to each warrant as well, for a combined cash outlay of roughly $49,976 (~$50k). The Form 4 reports the securities as an award/acquisition (code A).

Key Details

• Transaction date: February 3, 2026; Form 4 filed February 5, 2026 (timely filing).
• Shares acquired: 2,060 common shares at $12.13 each (total $24,988 reported for shares).
• Derivative acquired: Warrants to purchase 2,060 common shares; footnote states the purchase price for each warrant was $12.13 (filing shows N/A price line for derivative).
• Warrant terms (footnote): expire on the earlier of (i) Feb 3, 2031 or (ii) within 60 days after a public announcement or Form 8-K disclosing topline data from PMN310 single ascending dose cohorts.
• Corporate action note: Filing reflects a 1-for-25 reverse split of common shares effective Nov 28, 2025.
• Shares owned after transaction: Not specified in the provided excerpt of the filing.
• Transaction code: A = Award/Grant/Other acquisition. No indication of sale or cashless exercise.

Context
This was a direct private purchase (Securities Purchase Agreement) rather than an open-market trade. The warrants are derivative securities giving the holder the right to buy shares under the stated terms; they are not immediate additional shares unless exercised. The purchase amount (~$50k) is modest relative to many insider transactions; purchases can be interpreted as a form of insider acquisition but do not, by themselves, prove future company performance.